ClinicalTrials.gg
Active, not recruitingNCT05705973NAGOMI COMPLEXUpdated Jul 10, 2026

Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

An observational study in Cardiovascular Disease, Coronary Artery Occlusion and Ischemic Heart Disease, sponsored by Terumo Europe N.V.. Active, not recruiting at 52 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Primary conditionMyocardial IschemiaRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Myocardial Ischemia
Why
  1. The study's listed conditions name Myocardial Ischemia, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Terumo Europe N.V. (part of Terumo Corporation) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 63 studies in Myocardial Ischemia with a site in France — 10 open to participants now, 14 under way, none of them phase 3. Myocardial Ischemia · France.

Enrollment
2nd of 19
3,000 · median 1,000
Started
2023
with 2 others
Observational
19 of 63
3 open now
Primary completion
2026-07
later than 4 of 13 live
Registered
58th of 63
by date

Among the 63 studies in Myocardial Ischemia with a site in France, this one is the 2nd largest by enrollment of the 19 observational ones that give a count, is one of 3 that started in 2023, is one of 19 observational ones, reaches primary completion later than 4 of the 13 other live ones, and was the 58th registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

10 of the 63 studies in Myocardial Ischemia with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Myocardial Ischemia with a site in France, or all of them as a file.
02

Study summary

The NAGOMI COMPLEX PMCF (Post-Market Clinical Follow-up) study has been designed to expand the knowledge about outcomes with the Ultimaster Nagomi™ sirolimus eluting coronary stent system (Ultimaster Nagomi™) in complex PCI subjects. The features for a complex PCI are based upon subgroup analysis of earlier published studies.

Read the detailed description

The study is a prospective, multi-center, post-market, non-interventional, observational, single-arm study. Subjects with an indication for a PCI according to current European Society of Cardiology (ESC) or national guidelines will be treated with the Ultimaster Nagomi™ in accordance with the intended use. The PCI procedure will be per hospital routine including the option, as per physician preference, to assess the functional severity of the lesion, perform intra-coronary imaging, use lesion preparation devices or to perform a staged procedure. Also, post-procedural anti-platelet medication will be per ESC or national guidelines.

The primary endpoint is Target Lesion Failure (TLF) defined as Cardiovascular Death (CD), Target-Vessel related Myocardial Infarction (TV-MI) and Clinically Driven Target Lesion Revascularization (CD-TLR) at 1 year. Secondary endpoints are a broad set of clinical endpoints defined by the Academic Research Consortium-II to fully characterize the performance of the Ultimaster Nagomi™ stent. Clinical events will be adjudicated by an independent Clinical Events Committee (CEC) to ensure a consistent assessment versus the event definitions. The Data Monitoring Committee (DMC) will simultaneously conduct regular review for accumulating data to ensure proper safety data monitoring. Core lab analysis of the baseline angiograms of bifurcation lesions by Quantitative Coronary Angiography (QCA) will be included. Procedural resource data will be collected for health-economic analysis. Subject reported outcomes will be documented using the EQ-5D-5L questionnaire and the Seattle Angina Questionnaire (SAQ) for the assessment of the quality of life and angina status, respectively.

The study will enroll 3,000 patients from European sites. Follow-up will be 2 years, except for subjects in whom no Ultimaster Nagomi™ stent was implanted and subjects that do not meet the inclusion criteria for a complex PCI as ascertained after the index procedure. These subjects will be followed until discharge.

03

Conditions studied

  • Cardiovascular Disease
  • Coronary Artery Occlusion
  • Ischemic Heart Disease

Browse trials for

Keywords

  • Percutaneous Coronary Intervention
  • Complex Bifurcation Lesion
04

In context

Myocardial Ischemia Reclassified

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

This study's enrollment of 3,000 is above the median of 318 across 398 observational studies indexed under Myocardial Ischemia.

Browse Myocardial Ischemia studies →

Lead sponsor

Terumo Europe N.V. is the lead sponsor of 25 studies on the registry; 1 is open to participants now.

Compared within Myocardial Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects who have signed the informed consent are considered enrolled upon insertion of the first Ultimaster NagomiTM stent is successfully implanted and the complex procedure criteria are confirmed. It is expected that study enrolment will take approximately 1.5 years. Enrolment will be competitive, i.e. enrolment will be closed once the total number of subjects has been reached irrespective of the number of subjects per individual site. Individual sites can not enroll more than 300 subjects.

The enrolled patient population is expected to be representative for complex patients because of the limited exclusion criteria and the participation of multiple sites from across Europe

Eligibility criteria

General Inclusion Criteria:

  1. Age ≥ 18 years
  2. Patient has been informed of the nature of the study and agrees to its provisions, has provided written as approved by the Institutional Review Board/Ethics Committee of the respective clinical site
  3. Ischemic heart disease with an indication for a PCI with, if available and per hospital guidelines, Heart Team consensus for a PCI procedure
  4. Intention to treat all lesions requiring a PCI with the Ultimaster Nagomi stent

Complex Procedure Inclusion Criteria

Subject meets ≥ 1 of the complex procedure criteria:

  1. Multivessel PCI defined as ≥ 2 native coronary arteries and/or venous or arterial bypass grafts treated with a stent
  2. ≥ 3 stents implanted
  3. ≥ 3 lesions treated
  4. Complex bifurcation lesion defined as true bifurcation lesion (Medina 1.1.1, 1.0.1 or 0.1.1) with a side branch diameter ≥ 2.5 mm plus one of the following:

i) side branch disease > 10 mm ii) calcified lesion iii) thrombotic lesion

e) Bifurcation lesion implanted with two stents

f) Total stent length implanted > 60 mm

g) Chronic total occlusion defined as a 100% occlusion with antegrade TIMI 0 flow with at least a 3-month duration

h) Left main stenting (main stem and/or bifurcation)

i) In-stent restenosis

j) Severe calcified lesion with use of atherectomy, lithotripsy or cutting balloon

Exclusion Criteria:

  1. Any surgery requiring general anaesthesia, comorbidity or indication likely necessitating the discontinuation of dual anti- therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines
  2. or to aspirin, heparin, L605 cobalt-chromium alloy, sirolimus or its structurally related compounds, lactide polymers or caprolactone polymers that cannot be pre-medicated
  3. Known contrast sensitivity that cannot be premedicated
  4. Pregnant and breastfeeding women
  5. \< 1 year for any cardiac or non-cardiac cause
  6. Participation in another clinical study that has not yet completed its primary endpoint
  7. Earlier enrolment in the Nagomi Complex study
  8. Unlikely to be available for follow-up during the duration of the study (2 years)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
3,000 participants (actual)
Target follow-up
2 Years
Patient registry
Yes

Interventions

  • DeviceUltimaster Nagomi™

    The Ultimaster NagomiTM Sirolimus eluting coronary stent system with Rapid Exchange Balloon Delivery System consists of a balloon expandable intra-coronary L605 cobalt chromium (CoCr) stent with abluminal drug eluting coating, that consists of a blend of Sirolimus and Poly(D,L-lactide-co-caprolactone), pre-mounted onto a high pressure, semi-compliant balloon delivery catheter

07

What researchers measure

Primary outcomes

  1. Target Lesion Failure (TLF)

    Defined as the composite of cardiovascular death, target-vessel related myocardial infarction and clinically driven target lesion revascularization.

    Time frame: at 1-year post procedure

Secondary outcomes

  1. Delivery success

    Delivery success is defined as an achievement of successful delivery of study stent to the target lesion, expansion of the study stent and withdrawal of the delivery catheter.

    Time frame: Intraoperative

  2. Lesion success

    Lesion success is defined as the attainment of \< 30% residual stenosis by visual estimate and/or \< 50% (by QCA) using any percutaneous method (if QCA was not available, the visual estimate of diameter stenosis is used).

    Time frame: Intraoperative

  3. Device success

    Device Success is defined as delivery success with the achievement of a final residual diameter stenosis of the target lesion of \< 30% by visual assessment and/or \< 50% by QCA, using the assigned device only.

    Time frame: Intraoperative

  4. Procedure success

    Procedure Success is defined as the achievement of \< 30% residual stenosis by visual assessment in all target lesions using any percutaneous method without the occurrence of death, Q wave or WHO defined non-Q wave, or repeat revascularization of the target lesion during the hospital stay.

    Time frame: during hospitalization, approximately 3 days

  5. Target lesion failure (TLF)

    The composite of cardiovascular death, MI (not clearly attributable to a nontarget vessel) and clinically driven Target lesion revascularization (TLR).

    Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years

  6. Patient oriented composite endpoint (POCE)

    Defined as composite of all-cause mortality, any MI and any coronary revascularization.

    Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years

  7. Death and subclassifications

    Death may be subclassified as: Cardiovascular death, Noncardiovascular death or Undetermined death. Cardiovascular death may include death caused by acute MI, death caused by sudden cardiac death, including unwitnessed, death resulting from heart failure, death caused by stroke, death caused by cardiovascular procedures, death resulting from cardiovascular hemorrhage, death resulting from other cardiovascular cause. Noncardiovascular death may include death from malignancy, death resulting from pulmonary causes, death caused by infection (including sepsis), death resulting from gastrointestinal causes, death resulting from accident/trauma, death caused by other noncardiovascular organ failure, death resulting from other. Undetermined cause of death is defined as a death not attributable to any other category because of the absence of any relevant source documents.

    Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years

  8. Myocardial infarction and subclassifications

    Myocardial infarction - Absolute rise in cardiac troponin (from baseline) ≥35 times upper reference limit, plus 1 (or more) of the following criteria: * New significant\* Q waves or equivalent * Flow-limiting angiographic complications * New "substantial" loss of myocardium on imaging \* Q-wave criteria requires the development of new Q waves ≥40 ms in duration and ≥1 mm deep in voltage in ≥2 contiguous leads.

    Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years

  9. Revascularization and subclassifications

    Successful revascularization of all lesions with angiographically a diameter stenosis ≥ 50%

    Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years

  10. Stent thrombosis (ST) and subclassifications

    Definite ST Presence of a thrombus that originates in the stent/scaffold or in the segment 5mm prox. or dist. to the stent/scaffold or in a side branch originating from the stented/scaffolded segment \& at least 1 of the ff: Acute onset of ischemic symptoms at rest New ECG changes suggestive of acute ischemia Typical rise and fall in cardiac biomarkers Or Pathological confirmation of thrombosis Evidence of recent thrombus within the stent/scaffold determined at autopsy Examination of tissue retrieved ff. thrombectomy Probable ST Any MI that is related to documented acute ischemia in the territory of the implanted stent/scaffold w/out angiographic confirmation of stent/scaffold thrombosis and in the absence of any other obvious cause. Occlusive thrombus Thrombolysis in MI grade 0/1 flow w/in or prox. to a stent/scaffold segment. Nonocclusive thrombus Intracoronary thrombus defined as a noncalcified filling defect or lucency surrounded by contrast material seen in mu

    Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years

  11. Bleeding (Bleeding Academic Research Consortium (BARC) 3-5)

    Type 3:Clinical, lab, and/or imaging evidence of bleeding w/ specific healthcare provider responses, as below: Type 3a Any BT with overt bleeding Overt bleeding plus Hgb drop ≥3 to \< 5 g/dL Type 3b Overt bleeding plus Hgb drop ≥5 g/dL Cardiac tamponade Bleeding requiring surgical intervention for control Bleeding requiring IV vasoactive drugs Type 3c Intracranial hemorrhage Type 4:CABG-related bleeding Perioperative intracranial bleeding w/in 48 hr Reoperation after closure of sternotomy for bleeding control Transfusion of ≥5 U whole blood or packed RBC w/in a 48-hr period Chest tube output ≥2 L w/in a 24-hr period Type 5:Fatal bleeding Bleeding that directly causes death with no other explainable cause. Categorized as: Type 5a Probable bleeding that is clinically suspicious as the cause of death, but bleeding is not directly observed and no autopsy or confirmatory imaging. Type 5b Definite bleeding that is directly observed (clinical specimen or imaging)

    Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years

  12. Balance between bleeding (BARC 3-5) and thrombotic event (myocardial infarction and/or stent thrombosis)

    The number of patients with a BARC 3-5 bleeding in comparison to the number of patients with a myocardial infarction and/or a stent thrombosis.

    Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years

  13. Utilization of cardiovascular health care resources

    Number of devices used during the procedure and use of anti-platelet and anti-thrombotic medication during the follow-up period.

    Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years

  14. Quality of Life assessment

    Quality of Life assessed as per EuroQl five-dimensional (EQ-5D) questionnaire: The first part of the questionnaire contain descriptive questions on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, each with 5 levels of responses. The second part of the questionnaire contains a standard vertical 20-cm visual analog scale that is calibrated from 'the worst health you can imagine' (scored 0) at its base to 'the best health you can imagine' (scored 100) at its apex.

    Time frame: at baseline, 30 days, 6 months, 1 year, and 2 years

  15. Angina status assessment Seattle Angina Questionnaire (SAQ)

    Angina status will be assessed through the Seattle Angina Questionnaire (SAQ). The SAQ is a validated disease-specific instrument for assessing the health status of patients with coronary artery disease. Scoring: Scores range from 1-100 with higher scores indicating better health

    Time frame: at baseline, 30 days, 6 months, 1 year, and 2 years

  16. QCA of the index procedure angiogram for a subset of patients with a Complex Bifurcation Lesion (CBL)

    Luminal dimensions of bifurcation lesions will be measured by off-line quantitative coronary angiography by a central core laboratory. The objective of the QCA is to quantitate and express the benefit of the Proximal Optimisation Technique (POT). The POT balloon positioning is of importance in this technique as well as the balloon diameter to obtain optimal stent apposition in the main branch.

    Time frame: procedure

08

Study locations

52 sites
09

References and documents

Publications

  • Mamas M, Stankovic G, Byrne RA, Chevalier B, Aminian A. Clinical, procedural and patient-reported outcomes of the Ultimaster Nagomi sirolimus-eluting coronary stent in complex percutaneous coronary intervention: the NAGOMI COMPLEX prospective cohort study protocol. BMJ Open. 2026 Jul 7;16(7):e116572. doi: 10.1136/bmjopen-2026-116572. PubMed 42414012 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jul 2026, 38 months.

Of 39 industry-sponsored observational studies under Myocardial Ischemia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's 38 months is above that.

Counting every sponsor, half of 204 studies reached it within 40 months; a quarter within 21 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2022
First posted
Jan 31, 2023
StartActual
Apr 25, 2023
Primary completionActual
Jul 3, 2026
CompletionEst.
Apr 29, 2027
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05705973
Lead sponsor
Terumo Europe N.V.
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Apr 25, 2023
Primary completion
Jul 3, 2026
Completion
Apr 29, 2027 (estimated)
Last update
Jul 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion